Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies (THTX) announced promising preclinical findings for its peptide-drug conjugate TH1902, showing superior anti-metastatic activity compared to docetaxel in a lung cancer model. These results, particularly in SORT1+ cancers, suggest potential effectiveness in treating difficult-to-manage metastasis. A live webcast is scheduled to provide additional insights into TH1902 and the SORT1+ Technology. The company aims to leverage SORT1 receptors, prevalent in numerous cancer types, to enhance treatment efficacy and reduce toxicity. The FDA has granted fast track designation to TH1902 for relevant cancers.
Theratechnologies has announced a KOL webinar scheduled for June 21, 2021, at 11:00 a.m. ET, focusing on their SORT1+ Technology™ and TH1902, an investigational peptide-drug conjugate for treating sortilin-expressing advanced solid tumors. The webinar will feature Dr. Richard Béliveau from Université du Québec à Montréal and updates from the company's executives. Notably, TH1902 has received fast track designation from the FDA for advanced solid tumors that are resistant to standard therapy, and it is currently in a Phase 1 clinical trial.
Theratechnologies announces the appointment of André Dupras as Vice President of Human Resources, effective immediately. Mr. Dupras brings over 25 years of HR experience, having previously held leadership roles at Clementia Pharmaceuticals and Pfizer Canada. His expertise is expected to help Theratechnologies attract and retain top talent, crucial for advancing its commercial objectives and research pipeline. Paul Lévesque, the Company’s CEO, highlighted the significance of Mr. Dupras’s role in strengthening the team amidst a competitive talent market.
Theratechnologies Inc. (THTX) presented positive results at the ACTHIV 2021 conference, highlighting patient satisfaction and compliance with Trogarzo®. A survey of 30 patients revealed that 100% reported satisfaction with the treatment experience, while 98% compliance was noted in a retrospective evaluation involving 130 patients. Additionally, 93% of patients found the IV infusion process convenient, and 87% expressed a high level of satisfaction. The findings underscored Trogarzo® effectiveness in supporting treatment adherence among HIV patients.
On May 18, 2021, Theratechnologies (NASDAQ: THTX, TSX: TH) announced that CEO Paul Levesque will participate in a virtual fireside chat hosted by Edward Nash at Canaccord Genuity on May 20, 2021, at 2:00 p.m. ET. The event will be accessible via a live webcast on the company’s website, providing insights into its innovative therapies aimed at addressing unmet medical needs. The company emphasizes its commitment to developing and commercializing biopharmaceutical solutions.
Theratechnologies held its annual meeting of shareholders on May 13, 2021, where all proposed candidates for the Board of Directors were elected. KPMG LLP was reappointed as auditors. Notable elections included Alain Trudeau, Andrew Molson, and Joseph Arena, who will contribute to the company’s growth in oncology, NASH, and HIV. The management expressed optimism about the company’s progress in 2020 continuing into 2021. Forward-looking statements highlight potential developments in their product pipeline, but also caution against risks affecting future performance.
Theratechnologies (THTX) reported its Q1 Fiscal 2021 results, revealing a net loss of $5,922,000 or $0.07 per share, compared to a loss of $4,544,000 for the same period last year. Consolidated revenue decreased by 1.8% to $15,430,000, driven by a decline in Trogarzo® sales, which fell by 6.4%. However, EGRIFTA SV® sales grew by 2.0%. The company's R&D expenses rose significantly to support oncology and NASH programs. Key updates include the initiation of a Phase 1 trial for TH1902 and progress towards a Phase 3 trial for tesamorelin in treating NASH.
Theratechnologies (NASDAQ: THTX) announced that Paul Levesque, President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 10:30 a.m. ET. The event will be accessible via a live webcast, with the link provided for attendees. This conference highlights the company’s focus on developing innovative therapies to meet unmet medical needs.
For more information about Theratechnologies, interested parties can visit their website.
Theratechnologies Inc. (THTX) announced it will report its Q1 fiscal 2021 financial results on April 14, 2021, ending February 28, 2021. A conference call will follow at 8:30 a.m. ET, hosted by CEO Paul Lévesque, to discuss these results. The call is open to financial analysts, while others can listen in. Participation details include toll-free and international dialing options, as well as a webcast link. An audio replay of the call will be available until April 21, 2021, with access codes provided for convenience.
Theratechnologies has announced promising results for its lead investigational drug, TH1902, presented at the 2021 AACR Annual Meeting. Preclinical data show that TH1902 demonstrates sustained tumor regression and superior anti-tumor activity compared to docetaxel across multiple cancer types, including melanoma and triple-negative breast cancer. The FDA has granted fast-track designation for TH1902, highlighting its potential in treating sortilin positive solid tumors. The ongoing Phase 1 trial aims to evaluate TH1902's safety and efficacy.
